Compare McKesson Corporation (MCK) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs 3M Company — how do they compare? McKesson Corporation trades at $824.56 (market cap $97.35B), while 3M Company trades at $172.86 (market cap $82.99B). The key difference: McKesson Corporation is the larger of the two by market cap, and 3M Company pays the higher dividend (1.96%). Which is the better fit depends on your goals.
| MCK | MMM | |
|---|---|---|
Market Cap | $97.35B | $82.99B |
Sector | Health | Industrials |
52-Week High | $995.69 | $174.61 |
52-Week Low | $659.01 | $141.10 |
Enterprise Value | $101.98B | $91.39B |
Dividend Yield | 0.39% | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
3M (MMM) trades at $159.98, up 0.09% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $2.14, exceeding the $1.98 estimate, and maintains a strong net income margin of 11.14%. Analysts are divided with a 48.49% buy rating, and the consensus price target is $149.75. Recent news highlights Q2 earnings expectations and new partnerships, such as the Airbus A220 supply agreement.
The outlook for MMM is mixed; earnings momentum and cost optimization support growth, but valuation ratios like a P/E of 30.8 suggest premium pricing. Risks include consumer segment weakness and debt levels. Upside depends on Q2 results meeting the $2.27 EPS forecast, while downside could stem from macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
